Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/143785
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Sánchez-Ramón, Silvia | es_ES |
dc.contributor.author | Corbí, Angel L. | es_ES |
dc.contributor.author | Fidalgo, Á. G. | es_ES |
dc.contributor.author | Domínguez-Soto, Ángeles | es_ES |
dc.date.accessioned | 2017-02-10T13:07:46Z | - |
dc.date.available | 2017-02-10T13:07:46Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Curr Pharm Des 22(41):6300-6305 (2016) | es_ES |
dc.identifier.issn | 1381-6128 | - |
dc.identifier.uri | http://hdl.handle.net/10261/143785 | - |
dc.description | 16 p.-1 tab. | es_ES |
dc.description.abstract | Cumulative recent evidence from clinical trials, observational studies and case reports has shown that subcutaneous administration of immunoglobulin (SCIg) exerts similar immunomodulatory capacity than intravenous immunoglobulin (IVIg) in autoimmune neurological diseases. Besides the beneficial clinical effects, the profile of safety and autonomy for the patient is higher for SCIg, while it is cost-saving in terms of the health resources used. However, there are still very few approved indications for SCIg and a certain resistance to choose SCIg for other autoimmune conditions even despite patients' interests. Here we present an updated review of the known immunomodulatory mechanisms of action of Ig and the current hypothesis supporting the clinical and immunological advantages of SCIg over IVIg that derive from their specific pharmacokinetic features. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Bentham Science Publishers | es_ES |
dc.relation.isversionof | Postprint | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | Subcutaneous immunoglobulin | es_ES |
dc.subject | Immunomodulation | es_ES |
dc.subject | Mechanisms of action | es_ES |
dc.title | Subcutaneous immunoglobulins: a promising alternative for immunomodulation? | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.2174/1381612822666160831103806 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.2174/1381612822666160831103806 | es_ES |
dc.identifier.e-issn | 1873-4286 | - |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Current Pharm. Design 2016.doc | Postprint | 467,5 kB | Microsoft Word | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
3
checked on 17-abr-2024
WEB OF SCIENCETM
Citations
3
checked on 29-feb-2024
Page view(s)
931
checked on 24-abr-2024
Download(s)
341
checked on 24-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.